Monday, 10 February 2014

Cladribine..thrown away by the FDA and EMA

Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; on behalf of the oral cladribine for early MS (ORACLE MS) Study Group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Feb 3. pii: S1474-4422(14)70005-5.

BACKGROUND: Patients who develop relapsing-remitting multiple sclerosis (MS) present with a first clinical demyelinating event. In this double-blind, multicentre, randomised, phase 3 study we investigated the effect of oral cladribine on conversion to clinically definite MS in patients with a first clinical demyelinating event, when given at the same doses shown to be effective in relapsing-remitting MS.

METHODS: Between Oct 21, 2008, and Oct 11, 2010, we recruited patients aged 18-55 years, inclusive, from 160 hospitals, private clinics, or treatment centres in 34 countries. Eligible patients had a first clinical demyelinating event within 75 days before screening, at least two clinically silent lesions of at least 3 mm on a T2-weighted brain MRI scan, and an Expanded Disability Status Scale score of 5·0 or lower. Patients with a first clinical demyelinating event ≤75 days before screening were randomly assigned (1:1:1) to receive cladribine tablets at cumulative doses of 5·25 mg/kg or 3·5 mg/kg or placebo. Randomisation was done with a central web-based randomisation system and was stratified by geographic region. Masking was maintained using a two-physician model. The primary endpoint of this 96-week study was time to conversion to clinically definite MS according to the Poser criteria. 

FINDINGS: Of 903 participants assessed for eligibility, 616 patients received cladribine 5·25 mg/kg (n=204), cladribine 3·5 mg/kg (n=206), or placebo (n=206). At trial termination on Oct 25, 2011, cladribine was associated with a risk reduction versus placebo for time to conversion to clinically definite MS (hazard ratio [HR] for 5·25 mg/kg=0·38, 95% CI 0·25-0·58, p<0·0001; HR for 3·5 mg/kg=0·33, 0·21-0·51, p<0·0001). Adverse events were reported in 165 (81%) patients in the cladribine 5·25 mg/kg group, 168 (82%) patients in the cladribine 3·5 mg/kg group, and 162 (79%) patients in the placebo group. We noted no increase in risk of adverse events with active treatment versus placebo apart from lymphopenia, which was a severe event in 10 (5%) patients in the 5·25 mg/kg group and four (2%) patients in the 3·5 mg/kg group.

INTERPRETATION: Both doses of cladribine significantly delayed MS diagnosis compared with placebo. The safety profile of cladribine was similar to that noted in a trial in patients with relapsing-remitting MS. 
     
Cladribine was shown in phase III (CLARITY) studies to be at least as active as Alemtuzumab in phase III studies but was much safer, as it did not cause the autoimmunities that occurs in about 20-30% of people taking Alemtuzumab(Lemtrada). It likewise was associated with as many cancers as found following the use of Alemtuzumab, or Gilenya and others for that matter. 

However, in the CLARITY trial there was unusually no cancers in the placebo group. This suggested a cancer risk of cladribine and caused the regulators in the EMA and FDA to ask for more safety studies. Another problems was the induction of leucopaenia (loss of white blood cells) that could lead to more cancer and infection problems. Loss of white blood cells is part of the action of the drug but the level of depletion could be in part controlled by dosing.
However in the trials the protocol meant repeat treatment without assessing the levels of white blood cells to determine if dosing was needed and so increase the risk of leucopaenia further. It is clear that cladribine could be an "induction therapy" taken as a short course within a year. Maybe you don't need to retreat

However, Merck Serono in their wisdom had only done one pivotal trial rather than the usual two, perhaps relying on the published data with generic clabribine.  They paid the price for this big mistake.

So rather than take the time to start another trial, with all the cost and importantly time entailed, they decided to pull the plug and withdraw oral clabribine from market. This was much to the glee of Novartis who were in the race to get the first oral drug for MS and Genzyme/Sanofi who have Lemtrada in their stable against which Movectro would compete. It was also good news for Biogen trailing in the wings with the development of tecfidera....

Why Did Merck pull the plug? 

Movectro was approved in Russia and Australia and so they were making some money but had not got the European and american markets which are the jewels in the Crown. By the time they had done another trial trial there would not be much patent life left. So the decision to cull the programme was probably for commercial rather than therapeutic reasons. Maybe Prof G will know this as he was PI on the CLARITY trial, but is probably gagged.

However, there were other commercial programmes on going at the time the oral cladribine (movectro) programme was pulled. One was cladribine verses beta interferon see the AAN 2013 meeting abstracts.

One trial reported here was called ORACLE, which treated people with clinically isolated syndrome. The drugs reduced the rate of conversion to clinically definite MS. Furthermore, if we look at the MRI data there was a relative failure in the control of disease activity in the first 3 months and then the activity flat lines. Some drugs take time to become active maybe along time for glaterimer acetate. So maybe if we re-baselined at 3 months then the effect of oral cladribine would have been much more impressive than it is. 
Were these people cured? 
Will there be follow-up of these people now the plug has been pulled? I don't know.

Furthermore, and importantly the increase cancer risk did not materialise and there were more cancers (i.e. at the natural background level of cancers) in placebo . This suggested that it was a false signal in the CLARITY trial and the regulators fears were unfounded.  

Therefore, the FDA and the EMA have thrown away a very useful opportunity. Will there be more studies on oral cladribine. Probably not unless Merck decide to do it. Movectro was a pro-drug of generic cladribine, a potentially "disruptive influence" (I got this term from a financial report. This relates to the business worlds view of Academic Neurologists bringing in a cheap drug to compete with the pharma machine) to the pharma MS cash cow.

What about other forms of (generic) of injectable cladribine. An opportunity? Any Neuros out there willing to try? The drug has been tarnished in the eyes of Neuros. Is the benefit good enough

     (Stylised graph overlaying different trials(interpret cautiously)

However, there are other me-too drugs that target this pathway such a Clofarabine another pill...but who has the licence on this?

Oh it looks like it could be Genzyme....Will they compete against their own alemtuzumab and develop it for MS....or is it stuck on a shelf as far a MS goes? Where's your money going on this one. Another could be Fludarabine,but who will pay for phase II and two phase III trials and the licensing costs. I bet No one. There is no academic glory in doing two phase III studies yet pharma and regulators (which incidently are largely funded by pharma about 86% for the EMA and about 100% for the MHRA) have created this requirement...which ensures the "disruptive influence" will never occur. Are there any Neuros out there that will prove me to be wrong on this

Thats why we need a big pharma alternative to incentivize pharma to do these studies.

Maybe ProfG will comment on this..it was his baby thrown out with the bathwater.

14 comments:

  1. It seems the FDA is being much more conservative in approving new MS therapies that could have an adverse impact in the longterm. I suspect this is a consequence of the Tysabri fiasco.

    ReplyDelete
    Replies
    1. I'm sure there's more than an element of truth to this.

      Delete
  2. Yes, the FDA doesn't have the budget for safety monitoring of some of these drugs. I think it is only fair that the manufacturer should bear the burdon of any safety monitoring concerns that should arise:

    http://articles.latimes.com/2006/oct/07/nation/na-fda7

    ReplyDelete
  3. The problem with the cancer risk in the cladribine data was that the placebo group was very atypical and the cancer risk was essentially at a level of cancer risk in the general population. However in a two year trial the real risks are unlikely to show themselves as the time frame is too short. The only by using the drug in real practise would one find out what the risks are and would be even clearer if you had a robust monitoring programme.

    ReplyDelete
  4. From the top graph above,it took 720 days to reach a flatline value of 15.9% of conversion to CDMS on the high dose Clabridine. This is the exact same results for Avonex shown on the lower graph.

    So, I think it is completely understandable that the FDA rejected clabradine given the safety profile of Avonex.

    ReplyDelete
    Replies
    1. The top and the bottom graphs are the same in relation of cladribine. In the bottom I have superimposed another trial and to make the point of the similarities it does not mean they are identical as the trials were not contemporary. I could do the same with tysabri verses placebo and tysabri verses beta interferons, the placebo and beta interferon overlay you can't use that approach to say beta interferon does not work.

      The safety profile of beta interferon is irrelevant to whether the FDA should approve cladribine or not the issue is the safety of cladribine.

      Delete
    2. Cladibrine has a 3% mortality rate in HCL. If the drug companies are so keen on introducing new chemotherapy based treatment for MS, they should be willing to evaluate the drug over a longer period of time and not pass the buck to the FDA. Just because you show efficacy in a two year trial does not mean the treatment is safe over the long term. This should have been the lesson from the Tysabri tradegy, but it looks like it's back to business as usual.

      Delete
  5. Interesting point. For Ms the two year trial may become a three year trial as regulators want disability outcomes. How long is long. Patent life is ticking durng these trials if you extend trials further will it haved ticked.Maybe it is time to overhaul patenting.For neurological conditions the time taken to get answers is too long.

    ReplyDelete
  6. Extending patent life sounds like a good solution. When can you make this happen?

    ReplyDelete
  7. Extending patient life sounds like no sort of outcome measurement I'd want for life!
    What happened to push the quantity of life as being more important than its quality?
    This point has been forgotten for a number of chronic conditions, I feel.
    sometimes I wonder whether researchers have their eyes on the longevity prize at the expense of lives well lived (I'm not just talking about MS research)

    ReplyDelete
  8. sorry, my mistake! I obviously had the patient's wellbeing taking priority over continued sales success, forgive me.

    ReplyDelete
  9. Well, if you want "highly effective" treatments that may have safety issues, you are going to have to test them longer. The drug companies don't want this and the regulatory agencies don't want to approve them. Maybe a compromise would be a special license that would mandate special monitoring to be able to subscibe the drug. I think the approach that is put in place for Tysabri is a good model. If this approach was implemented during the Tysabri launch instead of damage control, you would have less needless deaths and more data on the drug could be gathered outside of a trial.

    ReplyDelete
    Replies
    1. interesting comment. this exactly what is happening with lemtrada they are screening people monthly for 5 years.

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.